Related Experiment Video
Updated: Mar 26, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
7.5K
The current treatment of Hepatitis C
Andrea Arleo1, Alessandra Mangia
1Liver Unit, IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy - a.mangia@tin.it.
Minerva Gastroenterologica E Dietologica
|January 23, 2016
Summary
Direct-acting antivirals (DAAs) have transformed Hepatitis C Virus (HCV) treatment, offering high cure rates and oral administration. Ongoing research focuses on optimizing treatment duration and regimens for diverse patient groups.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Direct-acting antivirals (DAAs) represent a significant advancement in Hepatitis C Virus (HCV) treatment.
- DAAs target multiple stages of the viral lifecycle, leading to high sustained virologic response (SVR) rates.
Purpose of the Study:
- To review current DAA regimens for HCV, categorized by genotype.
- To summarize emerging treatment strategies and future directions in HCV therapy.
Main Methods:
- Review of current literature on DAAs for HCV treatment.
- Analysis of DAA combination strategies, including NS3/4, NS5A, and NS5B inhibitors.
- Discussion of treatment durations and outcomes in various patient populations, including those with cirrhosis.
Main Results:
- DAAs achieve SVR rates of 90% or higher, with oral administration regardless of liver disease severity.
- Combination therapies utilizing different DAA classes offer effective treatment options.
- Treatment durations are typically 12-24 weeks, with ongoing efforts to shorten this period.
Conclusions:
- DAAs have revolutionized HCV treatment, offering high efficacy and improved patient accessibility.
- Current treatment strategies demonstrate effectiveness even in complex patient populations like those with decompensated cirrhosis.
- The number of patients with unmet medical needs for HCV is expected to decrease significantly in the coming years.
Related Concept Videos
01:25Hepatitis
34
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
01:10Retrovirus Life Cycles
50.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.0K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.0K
01:30Inhibitors of Viral Protein Synthesis
17
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
17
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
01:28Pulmonary Tuberculosis V
768
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
768